SEP 28, 2021 9:00 AM PDT

New method for standardized, high-throughput PBMC isolation from blood samples for observational and clinical studies

Sponsored by: Miltenyi Biotec

Event Date & Time
Date:  September 28, 2021
Time: 9:00am (PDT),  12:00pm (EDT)
Standardization and reproducibility are prerequisites for peripheral blood mononuclear cell (PBMC) generation from donor or patient samples in PBMC-based studies. Whether you are analyzing transcriptional changes as part of a COVID study or screening cancer biomarkers from patient samples, high-quality, viable PBMCs are the starting point for reliable analyses. Most currently available methods are highly user-dependent, laborious, and require extensive hands-on experience to get reliable results. In this webinar, we present a new method of PBMC isolation from clinical or non-clinical blood samples: automated, standardized, and without the need for density gradient centrifugation. In order to minimize sample variation and ensure the quality of PBMCs, the Gutenberg COVID-19 cohort study used this method to generate pure and viable PBMCs from over 20,000 blood samples, allowing investigation of not only the direct effects of SARS-CoV-2 infection and COVID-19 disease progression, but also the comprehensive effects of the pandemic, and the measures to fight it, on the health of the population.
Learning Objectives
  • Discuss and understand the importance of standardization and quality of PBMC generation in observational and clinical studies
  • Describe how to obtain clean PBMCs without density gradient centrifugation from peripheral blood samples
  • Discuss the design, plan and execution of a PBMC-based observational study
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

You May Also Like
Loading Comments...